Cooley

Steven Holm

Counsel

sholm@cooley.com

+65 6962 7528

Singapore

Capital Markets
Asia
Life Sciences and Healthcare
Agricultural Sciences and Technology
Climate Tech
Emerging Companies
Debt Finance

Steven focuses his practice on advising public and private companies and investors across South and Southeast Asia on strategic transactions and corporate governance.

Steven is counsel to companies across an array of industries, ranging from startups to well established companies. He is passionate about the “bits and atoms” life sciences, agtech, deeptech and cleantech ecosystem in Southeast Asia and diversifying the new economy ecosystem.
Steven has significant experience in private financings, initial public offerings (IPOs), deSPAC (special purpose acquisition company) transactions, crossover rounds, follow-on offerings, debt financing rights issues, and ongoing securities law compliance with experience in introducing regional companies to international markets. He also advises venture capital and private equity funds and investment banking firms in connection with financings.

Most recently, Steven was named to Asian Legal Business' Singapore Rising Stars 2026 list, which recognizes Singapore's most promising lawyers.

Before joining Cooley, Steven worked in the Singapore and London offices of major international law firms.

Steven’s representative matters include*:

Life sciences and deeptech

- **Hummingbird Bioscience** on its spinout and out-license of Callio Therapeutics and investment in Callio’s $187 million Series A financing in the first Singapore-linked new company (NewCo) transaction
- **Enlitic** on its Australian IPO and subsequent follow-on capital raises, bolt-on acquisition and secured debt financing
- **Structure Therapeutics** on the establishment and takedowns from its at-the-market program
- The lead investor in the spin-out and financing of a **Singapore therapeutics company**
- The lead investor in **N&E Innovations**’ Series A private financing
- **Opthea** on several follow-on capital raisings and strategic transaction considerations
- **Inmagene Biopharmaceuticals** in its Nasdaq reverse merger with Ikena Oncology and private investment in public equity (PIPE) financing
- **ASLAN Pharmaceuticals** in its follow-on capital raisings, public company matters and IP-backed debt

facility
- **Hummingbird Bioscience** in its private fundraisings and strategic transactions
- **Summit Healthcare** (SPAC) in its US$849 million merger with YS Biopharma and deSPAC listing on Nasdaq
- **Welsbach** (SPAC) in its proposed merger listing with WaveTech, a battery technology company, and deSPAC listing on Nasdaq
- The lead investor in **1NHealth**'s Series A private financing
- **World View** in its proposed merger and deSPAC listing on the New York Stock Exchange
- A Singapore-based medical devices company in its proposed US and Singapore IPOs
- Several Asia-Pacific-headquartered and US-listed biotech and device companies in their public company matters
- Numerous private techbio, agbio and cleantech companies in their founder relationship structuring, investor engagements, equity and convertible financings, and pilot arrangements with multinationals

Technology

- **Bitdeer Technologies Group** on its $400 million principal amount of 4.00% convertible senior notes due 2031 and $147.8 million concurrent registered direct offering and derivatives transactions
- **Ambiq Micro** on its dual listing on the Singapore Exchange
- The **leading regulated USD stablecoin issuer** in its bolt-on M&A matters and Asia-Pacific expansion
- **WeRide** in its HK$2.39 billion homecoming IPO in Hong Kong and US-registered follow-on offering, following its IPO on Nasdaq
- **AvePoint** in its SG$260 million US Securities and Exchange Commission-registered follow-on offering with concurrent listing on the Singapore Exchange
- **New Energy Startups and Investors** in the geothermal, energy markets and battery chemistry spaces
- **Several digital asset treasury (DAT) companies** on their conversions from operating companies and subsequent follow-on, PIPE and ATM fundraisings, as well as DAT investors
- The placement agents in the **public M&A transaction** involving two Association of Southeast Asian Nations (ASEAN) superapps
- The underwriters in the Indian IPO of a **drone manufacturer**
- **Life360** in its US$179 million Nasdaq IPO and uplisting from the Australian Securities Exchange
- **Bitdeer Technologies Group** in its US$1.18 billion merger with Blue Safari (SPAC) and deSPAC listing on Nasdaq
- A **technology-led ASEAN quick commerce chain** in its Latin America expansion
- **Bukalapak** in its US$1.5 billion 144A Indonesian IPO*
- **Triterras** in one of the first Asian deSPAC transactions*
- **MoneyHero** in its ongoing public company matters
- **Aetherium** (SPAC) in its proposed US$1.15 billion merger with an arm of AirAsia and deSPAC listing
- **FinAccel** on its $270 million Series D private financing and proposed deSPAC transaction
- **Fluid** in its Series A private financing
- **Tiga Acquisition Corp.** in its SPAC IPO and eventual US$2.1 billion deSPAC transaction with Grindr*
- **20Cube Logistics** in its proposed deSPAC transaction
- Early-stage **agentic artificial intelligence (AI) companies** on their venture financings and incentive structures
- A leading Singapore-based ecommerce service provider in its attempted IPO transaction
- Several fintech lenders in their private debt financing matters
- An Indonesia-based logistics tech platform in its private financings and shareholder engagement strategy
- Several US-based software as a service multinationals on the impact of Singapore's LNLCo regulation on their Asia-Pacific holding companies and global environmental, social and governance (ESG) reporting strategy
- Several ASEAN e-wallet providers in their private financings, shareholder engagement and exit

considerations
- Numerous venture capital funds in their portfolios' post-listing shareholder reporting and liquidity matters

*Other industry verticals**

- An **ASEAN stock exchange** on its regulatory alignment to international IPO best practices
- The underwriters in the Indian IPO of **Duroflex**
- The underwriters in the Indian IPO of a **leading fast-casual restaurant chain**
- The underwriters in the Indian IPO of **Swara Baby Products**
- **Bank Rakyat Indonesia** in its 144A Indonesian rights issue to fund a material acquisition
- The underwriters in the Philippines IPO of **DDMP REIT**, the second real estate investment trust (REIT) IPO in the Philippines using an innovative structure
- **ASEAN regional roll-up transactions** for a technology-enabled consumer discretionary chain
- **Summarecon Agung** in its Reg S-only exclusionary rights issue and Reg S secondary placement
- **Tele2** in its US IPO on Form F-4, following its acquisition of Com Hem
- **GE Oil & Gas** in its spinout of GE and merger with Baker Hughes on Form S-4
- The initial purchasers in **Waberer**'s 144A Hungarian IPO, the largest IPO in Hungary since 1998 and first Central and Eastern Europe sponsor IPO exit
- **Lecta** in its proposed 144A Luxembourg IPO
- The placement agents in several Indian accelerated offers for sale (block trades)
- The underwriters in **NatWest Group**'s (fka The Royal Bank of Scotland Group) F-3 shelf takedowns and F-3 renewal
- The underwriters in **ArcelorMittal**'s F-3 shelf takedown
- The initial purchasers in several **PETRONAS** 144A global medium-term note program updates and takedowns
- **Indofood CBP** in its inaugural Reg S issuance, one of the first investment-grade debt issuances by a non-state-linked Indonesian company
- Ongoing Securities and Exchange Commission compliance and continuous disclosure for multiple foreign private issuers and certain domestic registrants

* Includes experience from prior firms

Education

Osgoode Hall, York University JD, 2016

York University, Schulich School of Business MBA, 2016

Thompson Rivers University BBA, Finance and Economics, honours, 2012

Admissions & Credentials

New York

Singapore (Registered Foreign Lawyer)

Not practicing Singapore law